ArticleScientific reports2026
Whole-genome sequencing and comparative genomic analysis of a novel Bacillus subtilis strain YE16 isolated from yak dung.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this study, genomic and functional characterization of the previously identified lignocellulolytic Bacillus sp. strain YE16 from an underrepresented ecological niche (yak dung) in the Sikkim Himalayas was performed-thus making it the first report of such a study of a strain from this region. Whole genome sequencing resolved the ambiguity regarding its taxonomic placement where it showed 98.63% ANI and 89.4% dDDH with the reference genome Bacillus subtilis subsp. subtilis 168, definitively assigning YE16 to B. subtilis. This was further confirmed by core-pangenome SNP based phylogenetic analysis, where the YE16 strain forms a separate branch on the phylogenetic tree, with a core-genome SNP distance of 33,807 relative to strain 168, indicating substantial strain-level genomic differentiation. YE16 encodes 43 strain specific genes with nutrient transportation, metabolism and defense mechanisms as the primary functional groups. The isolate possessed a total of 95 GHs, 83 GTs, 38 CBMs, consistent with the previously demonstrated lignocellulolytic phenotype. 18 biosynthetic gene clusters were identified with expanded lipopeptide-related NRPS clusters, of which 4 showed low similarity (< 50%). A single intact prophage related to Brevibacillus phage Osiris was also detected, augmenting its genomic variability. Preliminary biosafety assessment identified no major virulence-associated determinants or evidence of acquired multidrug resistance within the scope of the study. Based on its distinct phylogenetic position, strain-specific gene content, diverse CAZyme and Biosynthetic Gene Cluster (BGC) repertoires, and isolation from an underrepresented niche, YE16 represents a genomically distinct strain of Bacillus subtilis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.